These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 17178887)

  • 1. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer.
    Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML
    Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disruption of Rb/E2F pathway results in increased cyclooxygenase-2 expression and activity in prostate epithelial cells.
    Davis JN; McCabe MT; Hayward SW; Park JM; Day ML
    Cancer Res; 2005 May; 65(9):3633-42. PubMed ID: 15867358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptional regulation of the androgen signaling pathway by the Wilms' tumor suppressor gene WT1.
    Zaia A; Fraizer GC; Piantanelli L; Saunders GF
    Anticancer Res; 2001; 21(1A):1-10. PubMed ID: 11299720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.
    Sterbis JR; Gao C; Furusato B; Chen Y; Shaheduzzaman S; Ravindranath L; Osborn DJ; Rosner IL; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S; Cullen J; Petrovics G
    Clin Cancer Res; 2008 Feb; 14(3):758-63. PubMed ID: 18245536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.
    Walton TJ; Li G; McCulloch TA; Seth R; Powe DG; Bishop MC; Rees RC
    Prostate; 2009 Jun; 69(8):810-9. PubMed ID: 19189301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
    Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
    Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
    Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
    Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer.
    Miyoshi Y; Ishiguro H; Uemura H; Fujinami K; Miyamoto H; Miyoshi Y; Kitamura H; Kubota Y
    Prostate; 2003 Sep; 56(4):280-6. PubMed ID: 12858356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer.
    Kinoshita H; Shi Y; Sandefur C; Meisner LF; Chang C; Choon A; Reznikoff CR; Bova GS; Friedl A; Jarrard DF
    Cancer Res; 2000 Jul; 60(13):3623-30. PubMed ID: 10910077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
    Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differently regulated androgen receptor transcriptional complex in prostate cancer compared with normal prostate.
    Kinoshita M; Nakagawa T; Shimizu A; Katsuoka Y
    Int J Urol; 2005 Apr; 12(4):390-7. PubMed ID: 15948728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer.
    Gnanapragasam VJ; Leung HY; Pulimood AS; Neal DE; Robson CN
    Br J Cancer; 2001 Dec; 85(12):1928-36. PubMed ID: 11747336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.
    Stanbrough M; Bubley GJ; Ross K; Golub TR; Rubin MA; Penning TM; Febbo PG; Balk SP
    Cancer Res; 2006 Mar; 66(5):2815-25. PubMed ID: 16510604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen receptor versus erbB-1 and erbB-2 expression in human prostate neoplasms.
    Brys M; Stawinska M; Foksinski M; Barecki A; Zydek C; Miekos E; Krajewska WM
    Oncol Rep; 2004 Jan; 11(1):219-24. PubMed ID: 14654929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
    Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
    Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The loss of 5alpha-reductase type I and type II mRNA expression in metastatic prostate cancer to bone and lymph node metastasis.
    Habib FK; Ross M; Bayne CW; Bollina P; Grigor K; Chapman K
    Clin Cancer Res; 2003 May; 9(5):1815-9. PubMed ID: 12738739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
    Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
    Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-4 in patients with prostate cancer.
    Takeshi U; Sadar MD; Suzuki H; Akakura K; Sakamoto S; Shimbo M; Suyama T; Imamoto T; Komiya A; Yukio N; Ichikawa T
    Anticancer Res; 2005; 25(6C):4595-8. PubMed ID: 16334148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor level controlled by a suppressor complex lost in an androgen-independent prostate cancer cell line.
    Wang LG; Ossowski L; Ferrari AC
    Oncogene; 2004 Jul; 23(30):5175-84. PubMed ID: 15156193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.